^
Association details:
Biomarker:GSTP1 overexpression
Cancer:Glioma
Drug:temozolomide (DNA synthesis inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment

Published date:
12/22/2021
Excerpt:
This study recruited a total of 186 patients with HGG who were treated with temozolomide plus radiotherapy adjuvant regimen….Patients with GSTP1-H and GSTP1-L were observed in 33 cases and 32 cases, respectively. As exhibited in Figure 5, patients with GSTP1-H showed a trend of worse OS compared with those with GSTP1-L [median OS: 9.2 (95% CI: 3.01–15.39) months vs 16.3 (95% CI: 12.42–20.18) months], although the difference was not statistically significant (χ2=3.247, P=0.072).
DOI:
https://doi.org/10.2147/IJGM.S328810